SELL and GUCY1A1 Gene Polymorphisms in Patients with Unstable Angina
Abstract
:1. Introduction
2. Materials and Methods
2.1. Methods
2.2. Genotyping
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Deckers, J.W. Classification of myocardial infarction and unstable angina: A re-assessment. Int. J. Cardiol. 2013, 167, 2387–2390. [Google Scholar] [CrossRef]
- Yaghoubi, A.; Golmohamadi, Z.; Alizadehasl, A.; Azarfarin, R. Role of platelet parameters and haematological indices in myocardial infarction and unstable angina. J. Pak. Med. Assoc. 2013, 63, 1133–1137. [Google Scholar]
- Franco, A.J.D.; Caravante, M.P.; Navarro, M.F.J.; de Teresa Galván, E. Prevención y tratamiento del síndrome coronario agudo. Rev. Esp. Cardiol. 2006, 6, 36G–45G. [Google Scholar] [CrossRef]
- Libby, P. Inflammation in atherosclerosis. Nature 2002, 420, 868–874. [Google Scholar] [CrossRef]
- Kadono, T.; Venturi, G.M.; Steeber, D.A.; Tedder, T.F. Leukocyte rolling velocities and migration are optimized by cooperative L-selectin and intercellular adhesion molecule-1 functions. J. Immunol. 2002, 169, 4542–4550. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Atalar, E.; Aytemir, K.; Haznedaroğlu, I.; Ozer, N.; Ovünç, K.; Aksöyek, S.; Kes, S.; Kirazli, S.; Ozmen, F. Increased plasma levels of soluble selectins in patients with unstable angina. Int. J. Cardiol. 2001, 78, 69–73. [Google Scholar] [CrossRef]
- Haught, W.H.; Mansour, M.; Rothlein, R.; Kishimoto, T.K.; Mainolfi, E.A.; Hendricks, J.B.; Hendricks, C.; Mehta, J.L. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: Further evidence for chronic inflammation in ischemic heart disease. Am. Heart J. 1996, 132 (Pt 1), 1–8. [Google Scholar] [CrossRef]
- Serrano, C.V., Jr.; Rocha Giraldez, R.; Fernandes, J.L.; Nicolau, J.C.; Zweier, J.L.; Ramires, J.A. Platelet and leukocyte adhesion and activation in unstable angina and post-PTCA. Int. J. Cardiol. 2005, 99, 423–428. [Google Scholar] [CrossRef] [PubMed]
- Iida, A.; Nakamura, Y. High-resolution SNP map in the 55-kb region containing the selectin gene family on chromosome 1q24-q25. J. Hum. Genet. 2003, 48, 150–154. [Google Scholar] [CrossRef]
- Wie, Y.S.; Lan, Y.; Meng, L.Q.; Nong, L.G. The association of L-selectin polymorphisms with L-selectin serum levels and risk of ischemic stroke. J. Thromb. Thrombolysis 2011, 32, 110–115. [Google Scholar] [CrossRef]
- Liu, J.; Liu, J.X.; Xu, S.N.; Quan, J.X.; Tian, L.M.; Guo, Q.; Liu, J.; Wang, Y.F.; Shi, Z.Y. Association of P213S polymorphism of the L-selectin gene with type 2 diabetes and insulin resistance in Chinese population. Gene 2012, 509, 286–290. [Google Scholar] [CrossRef] [PubMed]
- Xia, Z.E.; Li, Y.; Ming, K.H.; Xiong, X.Q. [Association of L-selectin gene polymorphism with susceptibility to coronary heart disease]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi—Chin. J. Med. Genet. 2007, 24, 173–176. [Google Scholar]
- Takei, T.; Hiraoka, M.; Nitta, K.; Uchida, K.; Deushi, M.; Yu, T.; Nitta, N.; Tsuchiya, K.; Yumura, W.; Nihei, H.; et al. Functional impact of IgA nephropathy-associated selectin gene haplotype on leukocyte-endothelial interaction. Immunogenetics 2006, 58, 355–361. [Google Scholar] [CrossRef] [PubMed]
- Derzbach, L.; Bokodi, G.; Treszl, A.; Vásárhelyi, B.; Nobilis, A.; Rigó, J., Jr. Selectin polymorphisms and perinatal morbidity in low-birthweight infants. Acta Paediatr. 2006, 95, 1213–1217. [Google Scholar] [CrossRef]
- Kessler, T.; Wobst, J.; Wolf, B.; Eckhold, J.; Vilne, B.; Hollstein, R.; von Ameln, S.; Dang, T.A.; Sager, H.B.; Moritz Rumpf, P.; et al. Functional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus. Circulation 2017, 136, 476–489. [Google Scholar] [CrossRef] [PubMed]
- Kessler, T.; Wolf, B.; Eriksson, N.; Kofink, D.; Mahmoodi, B.K.; Rai, H.; Tragante, V.; Åkerblom, A.; Becker, R.C.; Bernlochner, I.; et al. Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. Cardiovasc. Res. 2019, 115, 1512–1518. [Google Scholar] [CrossRef]
- McGuigan, F.E.; Ralston, S.H. Single nucleotide polymorphism detection: Allelic discrimination using TaqMan. Psychiatr. Genet. 2002, 12, 133–136. [Google Scholar] [CrossRef] [PubMed]
- Livak, K.J. SNP genotyping by the 5′-nuclease reaction. Methods Mol. Biol. 2003, 212, 129–147. [Google Scholar] [CrossRef]
- Fuentes, E.; Palomo, I. Role of oxidative stress on platelet hyperreactivity during aging. Life Sci. 2016, 148, 17–23. [Google Scholar] [CrossRef] [PubMed]
- Procter, N.E.; Chong, C.R.; Sverdlov, A.L.; Chan, W.P.; Chirkov, Y.Y.; Horowitz, J.D. Aging of platelet nitric oxide signaling: Pathogenesis, clinical implications, and therapeutics. Semin. Thromb. Hemost. 2014, 40, 660–668. [Google Scholar] [CrossRef]
- Johnson, A.A.; Stolzing, A. The role of lipid metabolism in aging, lifespan regulation, and age-related disease. Aging Cell 2019, 18, e13048. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Papsdorf, K.; Brunet, A. Linking Lipid Metabolism to Chromatin Regulation in Aging. Trends Cell Biol. 2019, 29, 97–116. [Google Scholar] [CrossRef]
- Mutlu, A.S.; Duffy, J.; Wang, M.C. Lipid metabolism and lipid signals in aging and longevity. Dev. Cell 2021, 56, 1394–1407. [Google Scholar] [CrossRef]
- Felder, T.; Geltinger, F.; Rinnerthaler, M. Lipid droplets meet aging. Aging (Albany) 2021, 13, 7709–7710. [Google Scholar] [CrossRef]
- Sagris, M.; Theofilis, P.; Antonopoulos, A.S.; Oikonomou, E.; Paschaliori, C.; Galiatsatos, N.; Tsioufis, K.; Tousoulis, D. Inflammation in Coronary Microvascular Dysfunction. Int. J. Mol. Sci. 2021, 22, 13471. [Google Scholar] [CrossRef]
- Guo, Y.; Liu, R.; Chen, L.; Wu, W.; Zhang, S. Neutrophil activation and neutrophil derived neutrophil extracellular trap formation in patients with coronary artery ectasia. BMC Cardiovasc. Disord. 2020, 20, 101. [Google Scholar] [CrossRef] [Green Version]
- Ivetic, A.; Hoskins Green, H.L.; Hart, S.J. L-selectin: A Major Regulator of Leukocyte Adhesion, Migration and Signaling. Front. Immunol. 2019, 10, 1068. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Watany, M.M.; Abdou, S.; Elkolaly, R.; Elgharbawy, N.; Hodeib, H. Evaluation of admission levels of P, E and L selectins as predictors for thrombosis in hospitalized COVID-19 patients. Clin. Exp. Med. 2022, 1–9. [Google Scholar] [CrossRef]
- Rahman, I.; Collado Sánchez, A.; Davies, J.; Rzeniewicz, K.; Abukscem, S.; Joachim, J.; Hoskins Green, H.L.; Killock, D.; Sanz, M.J.; Charras, G.; et al. L-selectin regulates human neutrophil transendothelial migration. J. Cell Sci. 2021, 134, jcs250340. [Google Scholar] [CrossRef]
- Ivetic, A. A head-to-tail view of L-selectin and its impact on neutrophil behaviour. Cell Tissue Res. 2018, 371, 437–453. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ivetic, A. Signals regulating L-selectin-dependent leucocyte adhesion and transmigration. Int. J. Biochem. Cell Biol. 2013, 45, 550–555. [Google Scholar] [CrossRef] [PubMed]
- Sandoval-Pinto, E.; Padilla-Gutiérrez, J.R.; Hernández-Bello, J.; Martínez-Fernández, D.E.; Valdés-Alvarado, E.; Muñoz-Valle, J.F.; Flores-Salinas, H.E.; Valle, Y. Influence of haplotypes, gene expression and soluble levels of L-selectin on the risk of acute coronary syndrome. Gene 2017, 625, 31–41. [Google Scholar] [CrossRef] [PubMed]
- Ponthieux, A.; Herbeth, B.; Droesch, S.; Haddy, N.; Lambert, D.; Visvikis, S. Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: The Stanislas study. Atherosclerosis 2004, 172, 299–308. [Google Scholar] [CrossRef] [PubMed]
- Berardi, C.; Decker, P.A.; Kirsch, P.S.; de Andrade, M.; Tsai, M.Y.; Pankow, J.S.; Sale, M.M.; Sicotte, H.; Tang, W.; Hanson, N.; et al. Plasma and serum L-selectin and clinical and subclinical cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Transl. Res. 2014, 163, 585–592. [Google Scholar] [CrossRef] [Green Version]
- Cottam, D.R.; Schaefer, P.A.; Fahmy, D.; Shaftan, G.W.; Angus, L.D. The effect of obesity on neutrophil Fc receptors and adhesion molecules (CD16, CD11b, CD62L). Obes. Surg. 2002, 12, 230–235. [Google Scholar] [CrossRef]
- Cottam, D.R.; Schaefer, P.A.; Shaftan, G.W.; Velcu, L.; Angus, L.D. Effect of surgically-induced weight loss on leukocyte indicators of chronic inflammation in morbid obesity. Obes. Surg. 2002, 12, 335–342. [Google Scholar] [CrossRef]
- Zinellu, A.; Mangoni, A.A. Systematic Review and Meta-Analysis of the Effect of Statins on Circulating E-Selectin, L-Selectin, and P-Selectin. Biomedicines 2021, 9, 1707. [Google Scholar] [CrossRef]
- Wobst, J.; Schunkert, H.; Kessler, T. Genetic alterations in the NO-cGMP pathway and cardiovascular risk. Nitric Oxide 2018, 76, 105–112. [Google Scholar] [CrossRef]
- Hall, K.T.; Kessler, T.; Buring, J.E.; Passow, D.; Sesso, H.D.; Zee, R.Y.L.; Ridker, P.M.; Chasman, D.I.; Schunkert, H. Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin. Eur. Heart J. 2019, 40, 3385–3392. [Google Scholar] [CrossRef] [Green Version]
- Emdin, C.A.; Khera, A.V.; Klarin, D.; Natarajan, P.; Zekavat, S.M.; Nomura, A.; Haas, M.; Aragam, K.; Ardissino, D.; Wilson, J.G.; et al. Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling. Circulation 2018, 137, 222–232. [Google Scholar] [CrossRef]
- Li, J.L.; Liu, L.Y.; Jiang, D.D.; Jiang, Y.Y.; Zhou, G.Q.; Mo, D.C.; Luo, M. Associations between GUCY1A3 genetic polymorphisms and large artery atherosclerotic stroke risk in Chinese Han population: A case-control study. Lipids Health Dis. 2019, 18, 233. [Google Scholar] [CrossRef] [PubMed]
Parameters | Control Group n = 144 | Unstable Angina n = 232 | p * |
---|---|---|---|
Mean ± SD | Mean ± SD | ||
Age (years) | 67.44 ± 10.62 | 62.07 ± 9.68 | <0.00001 |
BMI (kg/m2) | 25.96 ± 3.64 | 28.37 ± 3.95 | <0.00001 |
CH (mg/dL) | 197.46 ± 40.98 | 230.27 ± 56.21 | <0.00001 |
HDL (mg/dL) | 53.04 ± 6.77 | 44.77 ± 8.40 | <0.00001 |
LDL (mg/dL) | 118.18 ± 36.84 | 163.70 ± 50.50 | <0.00001 |
TG (mg/dL) | 105.09 ± 45.92 | 139.77 ± 73.29 | <0.00001 |
n (%) | n (%) | p ˆ | |
Sex (male) | 54 (37.5%) | 172 (74.1%) | <0.0001 |
Arterial hypertension | 57 (39.6%) | 145 (62.5%) | <0.0001 |
Diabetes mellitus | 9 (6.3%) | 57 (24.6%) | <0.0001 |
Control Group | Unstable Angina | p Value ^ | Compared Genotypes or Alleles | p Value # | OR (95% CI) | |||
---|---|---|---|---|---|---|---|---|
n | % | n | % | |||||
GUCY1A1 rs7692387 genotype | ||||||||
GG | 91 | 63.19% | 146 | 62.93% | 0.439 | AA + GA vs. GG | 1.00 | 1.01 (0.66–1.56) |
GA | 45 | 31.25% | 79 | 34.05% | AA vs. GA + GG | 0.28 | 0.53 (0.19–1.49) | |
AA | 8 | 5.56% | 7 | 3.02% | AA vs. GG | 0.28 | 0.55 (0.19–1.56) | |
GA vs. GG | 0.73 | 1.09 (0.70–1.72) | ||||||
AA vs. GA | 0.26 | 0.50 (0.17–1.47) | ||||||
Allele | ||||||||
G | 227 | 78.82% | 371 | 79.96% | A vs. G | 0.71 | 0.93 (0.65–1.34) | |
A | 61 | 21.18% | 93 | 20.04% | ||||
SELLrs2205849 genotype | ||||||||
TT | 119 | 82.64% | 178 | 76.72% | 0.126 | CC + TC vs. TT | 0.19 | 1.44 (0.85–2.45) |
TC | 24 | 16.67% | 45 | 19.40% | CC vs. TC + TT | 0.10 | 5.77 (0.72–46.04) | |
CC | 1 | 0.69% | 9 | 3.88% | CC vs. TT | 0.10 | 6.02 (0.75–48.11) | |
TC vs. TT | 0.49 | 1.25 (0.73–2.17) | ||||||
CC vs. TC | 0.16 | 4.80 (0.57–40.17) | ||||||
Allele | ||||||||
T | 262 | 90.97% | 401 | 86.42% | C vs. T | 0.06 | 1.58 (0.98–2.57) | |
C | 26 | 9.03% | 63 | 13.58% | ||||
SELLrs2229569 genotype | ||||||||
GG | 118 | 81.94% | 179 | 77.15% | AA + GA vs. GG | 0.30 | 1. 34 (0.80–2.27) | |
GA | 25 | 17.36% | 44 | 18.97% | 0.152 | AA vs. GA + GG | 0.10 | 5.77 (0.72–46.04) |
AA | 1 | 0.70% | 9 | 3.88% | AA vs. GG | 0.10 | 5.93 (0.74–47.44) | |
GA vs. GG | 0.68 | 1.16 (0.67–2.00) | ||||||
Allele | AA vs. GA | 0.15 | 5.11 (0.61–42.75) | |||||
G | 261 | 90.62% | 402 | 86.64% | ||||
A | 27 | 9.38% | 62 | 13.36% | A vs. G | 0.11 | 1.49 (0.92–2.41) |
Control Group (n = 15) | Unstable Angina (n = 55) | p Value ^ | Compared Genotypes or Alleles | p Value # | OR (95% CI) | |||
---|---|---|---|---|---|---|---|---|
n | % | n | % | |||||
GUCY1A1rs7692387 genotype | ||||||||
GG | 7 | 46.67% | 34 | 61.82% | 0.025 | AA + GA vs. GG | 0.38 | 0.54 (0.17–1.71) |
GA | 5 | 33.33% | 20 | 36.36% | AA vs. GA + GG | 0.028 | 0.07 (0.01–0.78) | |
AA | 3 | 20.00% | 1 | 1.82% | AA vs. GG | 0.029 | 0.07 (0.01–0.76) | |
GA vs. GG | 0.75 | 0.82 (0.23–2.94) | ||||||
AA vs. GA | 0.052 | 0.08 (0.01–0.98) | ||||||
Allele | ||||||||
G | 19 | 63.33% | 88 | 80.00% | A vs. G | 0.087 | 0.43 (0.18–1.04) | |
A | 11 | 36.67% | 22 | 20.00% | ||||
SELLrs2205849 genotype | ||||||||
TT | 11 | 73.33% | 41 | 74.54% | 0.872 | CC + TC vs. TT | 1.00 | 0.94 (0.26–3.43) |
TC | 3 | 20.00% | 12 | 21.82% | CC vs. TC + TT | 0.52 | 0.53 (0.05–6.26) | |
CC | 1 | 6.67% | 2 | 3.64% | CC vs. TT | 0.53 | 0.54 (0.04–6.48) | |
TC vs. TT | 1.00 | 1.07 (0.26–4.48) | ||||||
CC vs. TC | 1.00 | 0.50 (0.03–7.54) | ||||||
Allele | ||||||||
T | 25 | 83.33% | 94 | 85.45% | C vs. T | 0.78 | 0.85 (0.28–2.55) | |
C | 5 | 16.67% | 16 | 14.55% | ||||
SELLrs2229569 genotype | ||||||||
GG | 11 | 73.33% | 41 | 74.54% | AA + GA vs. GG | 1.00 | 0.94 (0.26–3.43) | |
GA | 3 | 20.00% | 12 | 21.82% | 0.872 | AA vs. GA + GG | 0.52 | 0.53 (0.05–6.26) |
AA | 1 | 6.67% | 2 | 3.64% | AA vs. GG | 0.53 | 0.54 (0.04–6.48) | |
GA vs. GG | 1.00 | 1.07 (0.26–4.48) | ||||||
Allele | AA vs. GA | 1.00 | 0.50 (0.03–7.54) | |||||
G | 25 | 83.33% | 94 | 85.45% | ||||
A | 5 | 16.67% | 16 | 14.55% | A vs. G | 0.78 | 0.85 (0.28–2.55) |
Control Group (n = 129) | Unstable Angina (n = 177) | p Value ^ | Compared Genotypes or Alleles | p Value # | OR (95% CI) | |||
---|---|---|---|---|---|---|---|---|
n | % | n | % | |||||
GUCY1A1 rs7692387 genotype | ||||||||
GG | 84 | 65.12% | 112 | 63.28% | 0.899 | AA + GA vs. GG | 1.08 | 0.54 (0.67–1.74) |
GA | 40 | 31.01% | 59 | 33.33% | AA vs. GA + GG | 1.00 | 0.87 (0.26–2.92) | |
AA | 5 | 3.87% | 6 | 3.39% | AA vs. GG | 1.00 | 0.90 (0.27–3.05) | |
GA vs. GG | 0.71 | 1.11 (0.68–1.81) | ||||||
AA vs. GA | 0.76 | 0.81 (0.23–2.85) | ||||||
Allele | ||||||||
G | 208 | 80.62% | 283 | 79.94% | A vs. G | 0.92 | 1.04 (0.70–1.56) | |
A | 50 | 19.38% | 71 | 20.06% | ||||
SELLrs2205849 genotype | ||||||||
TT | 108 | 83.72% | 137 | 77.40% | 0.057 | CC + TC vs. TT | 0.19 | 1.50 (0.84–2.70) |
TC | 21 | 16.28% | 33 | 18.64% | CC vs. TC + TT | 0.022 | - | |
CC | 0 | 0.00% | 7 | 3.96% | CC vs. TT | 0.021 | - | |
TC vs. TT | 0.55 | 1.24 (0.68–2.26) | ||||||
CC vs. TC | 0.08 | - | ||||||
Allele | ||||||||
T | 237 | 91.86% | 307 | 86.72% | C vs. T | 0.051 | 1.73 (1.01–2.97) | |
C | 21 | 8.14% | 47 | 13.28% | ||||
SELLrs2229569 genotype | ||||||||
GG | 107 | 82.95% | 138 | 77.96% | AA + GA vs. GG | 0.31 | 1.38 (0.77–2.46) | |
GA | 22 | 17.05% | 32 | 18.08% | 0.068 | AA vs. GA + GG | 0.022 | - |
AA | 0 | 0.00% | 7 | 3.96% | AA vs. GG | 0.021 | - | |
GA vs. GG | 0.76 | 1.13 (0.62–2.05) | ||||||
Allele | AA vs. GA | 0.042 | - | |||||
G | 236 | 91.47% | 308 | 87.01% | ||||
A | 22 | 8.53% | 46 | 12.99% | A vs. G | 0.09 | 1.60 (0.94–2.74) |
Without | Diabetes | p Value ^ | p Value * | OR (95% CI) | ||||
---|---|---|---|---|---|---|---|---|
Diabetes | Mellitus | |||||||
Mellitus | ||||||||
n | % | n | % | |||||
SELLrs2229569 | ||||||||
genotype | ||||||||
GG | 134 | 76.57% | 45 | 78.95% | 0.63 | AA + GA vs. GG | 0.86 | 0.87 (0.42–1.80) |
GA | 33 | 18.86% | 11 | 19.30% | AA vs. GA + GG | 0.46 | 0.37 (0.05–3.05) | |
AA | 8 | 4.57% | 1 | 1.75% | AA vs. GG | 0.46 | 0.37 (0.05–3.06) | |
GA vs. GG | 1.00 | 0.99 (0.46–2.13) | ||||||
AA vs. GA | 0.67 | 0.38 (0.04–3.34) | ||||||
Allele | ||||||||
G | 301 | 86.00% | 101 | 88.60% | A vs. G | 0.53 | 0.79 (0.41–1.52) | |
A | 49 | 14.00% | 13 | 11.40% | ||||
SELL | ||||||||
rs2205849 | ||||||||
genotype | ||||||||
TT | 133 | 76.00% | 45 | 78.95% | 0.63 | CC + TC vs. TT | 0.72 | 0.84 (0.41–1.74) |
TC | 34 | 19.43% | 11 | 19.30% | CC vs. TC + TT | 0.46 | 0.37 (0.05–3.05) | |
CC | 8 | 4.57% | 1 | 1.75% | CC vs. TT | 0.46 | 0.37 (0.05–3.04) | |
TC vs. TT | 1.00 | 0.96 (0.45–2.04) | ||||||
CC vs. CT | 0.67 | 0.39 (0.04–3.44) | ||||||
Allele | ||||||||
T | 300 | 85.71% | 101 | 88.60% | C vs. T | 0.53 | 0.77 (0.40–1.48) | |
C | 50 | 14.29% | 13 | 11.40% | ||||
GUCY1A1 | ||||||||
rs7692387 | ||||||||
genotype | ||||||||
GG | 108 | 61.71% | 38 | 66.67% | 0.70 | AA + GA vs. GG | 0.53 | 0.81 (0.43–1.51) |
GA | 61 | 34.86% | 18 | 31.58% | AA vs. GA + GG | 1.00 | 0.50 (0.06–4.27) | |
AA | 6 | 3.43% | 1 | 1.75% | AA vs. GG | 0.68 | 0.47 (0.06–4.06) | |
GA vs. GG | 0.63 | 0.84 (0.44–1.60) | ||||||
AA vs. GA | 1.00 | 0.57 (0.06–5.00) | ||||||
Allele | ||||||||
G | 277 | 79.14% | 94 | 82.46% | A vs. G | 0.50 | 0.81 (0.47–1.40) | |
A | 73 | 20.86% | 20 | 17.54% |
Without | Arterial | p Value ^ | p Value * | OR (95% CI) | ||||
---|---|---|---|---|---|---|---|---|
Arterial | Hypertension | |||||||
Hypertension | ||||||||
n | % | n | % | |||||
SELLrs2229569 | ||||||||
genotype | ||||||||
GG | 67 | 77.01% | 112 | 77.24% | 0.14 | AA + GA vs. GG | 1.00 | 0.99 (0.52–1.86) |
GA | 14 | 16.09% | 30 | 20.69% | AA vs. GA + GG | 0.08 | 0.29 (0.07–1.17) | |
AA | 6 | 6.90% | 3 | 2.07% | AA vs. GG | 0.09 | 0.30 (0.07–1.24) | |
GA vs. GG | 0.60 | 1.28 (0.64–2.59) | ||||||
AA vs. GA | 0.07 | 0.23 (0.05–1.07) | ||||||
Allele | ||||||||
G | 148 | 85.06% | 254 | 87.59% | A vs. G | 0.48 | 0.81 (0.47–1.39) | |
A | 26 | 14.94% | 36 | 12.41% | ||||
SELL | ||||||||
rs2205849 | ||||||||
genotype | ||||||||
TT | 66 | 75.86% | 112 | 77.24% | 0.16 | CC + TC vs. TT | 0.87 | 0.93 (0.50–1.73) |
TC | 15 | 17.24% | 30 | 20.69% | CC vs. TC + TT | 0.08 | 0.29 (0.07–1.17) | |
CC | 6 | 6.90% | 3 | 2.07% | CC vs. TT | 0.09 | 0.30 (0.07–1.22) | |
TC vs. TT | 0.73 | 1.18 (0.60–2.35) | ||||||
CC vs. CT | 0.13 | 0.25 (0.06–1.14) | ||||||
Allele | ||||||||
T | 147 | 84.48% | 254 | 87.59% | C vs. T | 0.40 | 0.77 (0.45–1.32) | |
C | 27 | 15.52% | 36 | 12.41% | ||||
GUCY1A1 | ||||||||
rs7692387 | ||||||||
genotype | ||||||||
GG | 56 | 64.37% | 90 | 62.07% | 0.46 | AA + GA vs. GG | 0.78 | 1.10 (0.64–1.92) |
GA | 27 | 31.03% | 52 | 35.86% | AA vs. GA + GG | 0.43 | 0.44 (0.10–2.01) | |
AA | 4 | 4.60% | 3 | 2.07% | AA vs. GG | 0.43 | 0.47 (0.10–2.16) | |
GA vs. GG | 0.57 | 1.20 (0.68–2.12) | ||||||
AA vs. GA | 0.25 | 0.39 (0.08–1.87) | ||||||
Allele | ||||||||
G | 139 | 79.89% | 232 | 80.00% | A vs. G | 1.00 | 0.99 (0.62–1.59) | |
A | 35 | 20.11% | 58 | 20.00% |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Malinowski, D.; Zawadzka, M.; Safranow, K.; Droździk, M.; Pawlik, A. SELL and GUCY1A1 Gene Polymorphisms in Patients with Unstable Angina. Biomedicines 2022, 10, 2494. https://doi.org/10.3390/biomedicines10102494
Malinowski D, Zawadzka M, Safranow K, Droździk M, Pawlik A. SELL and GUCY1A1 Gene Polymorphisms in Patients with Unstable Angina. Biomedicines. 2022; 10(10):2494. https://doi.org/10.3390/biomedicines10102494
Chicago/Turabian StyleMalinowski, Damian, Magda Zawadzka, Krzysztof Safranow, Marek Droździk, and Andrzej Pawlik. 2022. "SELL and GUCY1A1 Gene Polymorphisms in Patients with Unstable Angina" Biomedicines 10, no. 10: 2494. https://doi.org/10.3390/biomedicines10102494